Download PDF
Thromb Haemost 1989; 61(03): 502-506
DOI: 10.1055/s-0038-1646623
Original Article
Schattauer GmbH Stuttgart

Potentiation by Lys-Plasminogen of Clot Lysis by Single or Two Chain Urokinase-Type Plasminogen Activator or Tissue-Type Plasminogen Activator

Y Watahiki
The Thrombosis Research Unit, King’s College School of Medicine & Dentistry London, UK
,
M F Scully
The Thrombosis Research Unit, King’s College School of Medicine & Dentistry London, UK
,
V Ellis
The Thrombosis Research Unit, King’s College School of Medicine & Dentistry London, UK
,
V V Kakkar
The Thrombosis Research Unit, King’s College School of Medicine & Dentistry London, UK
› Author Affiliations
Further Information

Publication History

Received 02 November 1988

Accepted after revision 06 March 1989

Publication Date:
24 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Study has been made of the influence of addition of human NH2 terminal glutamic acid plasminogen (Glu-Plg) or human NH2 terminal lysine plasminogen (Lys-Plg) to normal citrated plasma upon the rate of lysis of fully crosslinked plasma clots in the presence of single or two chain urokinase type plasminogen activator (scu-PA/tcu-PA) or tissue plasminogen activator (t-PA). The Specificity of any thrombolytic property was evaluated by measurement of plasma fibrinogen levels. Lys-plgadded to a concentration of 20% of normal plasma plasminogen caused 5 to 6 fold increase in the extent of lysis observed at 6 hours by 100 units/ml of scu-PA and with a small increase in fibrinogenolysis. Glu-Plg added at 20% of normal level had no influence on thrombolysis but at 50% of normal caused increased thrombolysis with rapid depletion of plasma fibrinogen. An apparently synergistic effect of addition of tcu-PA on scu-PA activity was increased by addition of plasminogen (e.g. addition of 20% Lys-Plg increased the lysis rate 4 to 5 fold over the first hour equivalent to an increase of potency of approximately three to four fold). Addition of plasminogen up to double the normal plasma concentration was observed to have no influence on clot lysis in the presence of t-PA. Plasminogen potentiated the rate of lysis by scu-Pr/t-PA synergic mixtures with an approximately 1.5 to 1.9 fold increase in potency. Potentiation occurred without increase in the depletion of plasma fibrinogen. It is concluded that Lys-Plg may be a suitable agent to improve the thrombolytic efficacy of scu-PA, scu-PA/tcu-PA or scu-PA/t-PA therapeutic regimen.

Keywords

Single chain urokinase-type plasminogen activator (scu-PA) - Urokinase - Tissue-type plasminogen activator (tPA) - Gluplasminogen - Lys-plasminogen - Clot lysis
 

  • Reference

  • 1 Gurewich V, Pannell R, Louie S, Kelley P, Suddith PL, Greenlee R. Effective and fibrin specific clot lysis by a zymogen precursor form of urokinase (UK). A study in vitro and in two animal species J Clin Invest 1984; 73: 1731-1739
    CrossrefPubMedGoogle Scholar
  • 2 Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase, Ill-Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemostas 1984; 52: 27-30
    PubMedGoogle Scholar
  • 3 Collen D, Stump D, Van de Werf F, Jang I K, Nobuhara M, Lijnen HR. Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. Circulation 1984; 72: 384-388
    PubMedGoogle Scholar
  • 4 Kominger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various species in vitro. Thromb Haemostas 1981; 46: 561-566
    PubMedGoogle Scholar
  • 5 Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus and route of administration J Clin Invest 1983; 71: 368-376
    CrossrefPubMedGoogle Scholar
  • 6 Gurewich V, Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 1986; 44: 217-228
    CrossrefPubMedGoogle Scholar
  • 7 Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC. Absence of synergism between tissue plasminogen activator (t-PA), single chain urokinase type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Haemostas 1986; 56: 35-39
    PubMedGoogle Scholar
  • 8 Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 1986; 774: 838-842
    PubMedGoogle Scholar
  • 9 Collen D, Stassen JM, De Cock F. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemostas 1987; 58: 943-946
    PubMedGoogle Scholar
  • 10 Kakkar VV, Sagar S, Lewis M. Treatment of deep vein thrombosis with intermittent streptokinase and plasminogen infusion. Lancet 1975; 2: 6174-6176
    PubMedGoogle Scholar
  • 11 Kakkar VV, Sagar S, Scully MF, Lane DA. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis. Aktuel Probl Angiol 1978; 37: 142-154
    PubMedGoogle Scholar
  • 12 Scully MF, Strachan CJ L, Kakkar VV. Binding of iodinated proteins to forming and preformed thrombi. Biochem Soc Trans 1973; 1: 1204-1206
    CrossrefPubMedGoogle Scholar
  • 13 Strachan CJ L, Scully MF, Kakkar VV. The behaviour of isotopic labelled blood proteins in thrombosis. Thromb Res 1974; 4: 303-318
    CrossrefPubMedGoogle Scholar
  • 14 Scully MF, Lane DA, Sagar S, Thomas DP, Kakkar VV. Intermittent plasminogen-streptokinase treatment of deep vein thrombosis. Thromb Haemostas 1977; 37: 162-169
    PubMedGoogle Scholar
  • 15 Welzel D, Wolf H. Clinical research on single chain urokinase-type plasminogen activator (scu-PA) in Germany. Results in patients with acute myocardial infarction (AMI) Thromb Haemostas 1987; 58: 47 Abstr
    PubMedGoogle Scholar
  • 16 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 17 Gurewich V, Pannell R. Synergism of tissue type plasminogen activator (t-PA) and single chain urokinase type plasminogen activator (scu-PA) on clot lysis in vitro and the mechanism of its effect. Thromb Haemostas 1987; 57: 372
    PubMedGoogle Scholar
  • 18 Collen D. Rebuttal. Synergism of tissue-type plasminogen activator (t- PA) and single chain urokinase type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect Thromb Haemostas 1987; 57: 373
    PubMedGoogle Scholar
  • 19 Claeys H, Molla A, Verstraete M. Conversion of NH2-terminal glutamic acid to NH2-terminal lysine human plasminogen by plasmin. Thromb Res 1973; 3: 515-523
    CrossrefPubMedGoogle Scholar
  • 20 Claeys H, Vermylen J. Physico-chemical and pro-enzyme properties of NH2-terminal lysine human plasminogen. Biochim Biophys Acta 1973; 342: 351-358
    PubMedGoogle Scholar
  • 21 Scully MF, Kakkar VV. Measurement of levels of degraded plasminogen during thrombolytic therapy. In: Chromogenic Peptide Substrate. Scully MF, Kakkar VV. eds Churchill Livingstone; Edinburgh: 1979. pp 141-153
    Google Scholar
  • 22 Takada A, Takada Y. Effects of w-amino acids and clot formation on the activation by urokinase of various plasminogen preparations. Thromb Res 1980; 18: 167-176
    CrossrefPubMedGoogle Scholar
  • 23 Collen D, Zamarron E, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase. J Biol Chem 1986; 261: 1259-1266
    PubMedGoogle Scholar
  • 24 Ellis V, Scully MF, Kakkar VV. Plasminogen activation by single chain urokinase in functional isolation. A kinetic study J Biol Chem 1987; 262: 14998-15003
    PubMedGoogle Scholar
  • 25 Thorsen S. Differences in binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of aminocarboxylic acids Biochim Biophys Acta 1975; 393: 55-62
    CrossrefPubMedGoogle Scholar
  • 26 Scully MF, Kakkar VV. Levels of degraded plasminogen during intermittent thrombolytic therapy. In: Progress in Chemical Fibrinolysis and Thrombolysis, Vol IV. Davidson JF, Cepalak V, Samama MM, Desnoyers PC. eds Churchill Livingstone; Edinburgh: 1979. pp 469-473
    Google Scholar
  • 27 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo J Biol Chem 1985; 260: 12106-12111
    PubMedGoogle Scholar
  • 28 Gurewich V, Black J, Pannell R. A mechanism for the potentiating effect of urokinase or tissue plasminogen activator on clot lysis by prourokinase. Thromb Haemostas 1987; 58: 439 Abstr
    PubMedGoogle Scholar
  • 29 Pannell R, Black J, Gurewich V. Complementary models of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 1988; 81: 853-859
    CrossrefPubMedGoogle Scholar
  • 30 Urano J, Sator de Serrano V, Gaffney PJ, Castellino FJ. The activation of human [Glu] plasminogen by human single-chain urokinase. Arch Biochem Biophys 1988; 264: 222-230
    CrossrefPubMedGoogle Scholar
  • 31 Scully MF, Ellis V, Watahiki Y, Kakkar VV. Activation of prourokinase by plasmin: Non-Michaelian kinetics indicates a mechanism of negative cooperativity. Arch Biochem Biophys. 1989 in press
    PubMedGoogle Scholar
  • 32 Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989 in press
    PubMedGoogle Scholar
  • 33 Collen D. Synergism, mutants and hybrids of tissue-type plasminogen activator (t-PA) and single chain urokinase type plasminogen activator (scu-PA): Potential for thrombolytic therapy. Thromb Haemostas 1987; 58: 254 Abstr
    PubMedGoogle Scholar
  • 34 Collen D, Ong EB, Johnson AJ. Human plasminogen: in vitro and in vivo evidence for the biological integrity of NH2-terminal glutamic acid plasminogen. Thromb Res 1975; 7: 515-529
    CrossrefPubMedGoogle Scholar